Pharmacokinetics and Safety of Triple Therapy with Vonoprazan, Amoxicillin, and Clarithromycin or Metronidazole: A Phase 1, Open-Label, Randomized, Crossover Study

Management of <i>Helicobacter pylori</i> infection—the Maastricht V/Florence Consensus Report

Peter Malfertheiner, Françis Mégraud, Colm O’Morain et al. · Gut · 2016 · 2.9K citations · Full text

Medicine, Infectious Diseases, Microbiology +13

Management of <i>Helicobacter pylori</i> infection—the Maastricht IV/ Florence Consensus Report

Peter Malfertheiner, Françis Mégraud, Colm O’Morain et al. · Gut · 2012 · 2.3K citations · Full text

Medicine, Clinical Sciences, Infectious Diseases +15

Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial

Kazutoshi Fukase, Mototsugu Kato, Shogo Kikuchi et al. · The Lancet · 2008 · 1.2K citations · Full text

Medicine, Oncology, Surgery +13

A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants

Sung Eun Sim, Carl Risinger, Eleni Aklillu et al. · Clinical Pharmacology & Therapeutics · 2006 · 729 citations

Medicine, Pharmacokinetics, Pharmacology +17

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for <i>Helicobacter pylori</i> eradication: a phase III, randomised, double-blind study

Kazunari Murakami, Yuuichi Sakurai, Madoka Shiino et al. · Gut · 2016 · 436 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15